A Phase 1 interventional study of ABBV-722 and Placebo in Healthy Volunteer, sponsored by AbbVie. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by AbbVie · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 1, first-in-human study to investigate safety, tolerability, and pharmacokinetics of ABBV-722 after oral dosing in healthy adult participants.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 2 only: Healthy Han Chinese and Japanese individuals between 18 and 65 years of age, inclusive at the time of Screening.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of either ABBV-722 Dose A or placebo.
Drug: ABBV-722 · Drug: Placebo
Participants will receive a single dose of either ABBV-722 Dose B or placebo.
Drug: ABBV-722 · Drug: Placebo
Participants will receive a single dose of either ABBV-722 Dose C or placebo.
Drug: ABBV-722 · Drug: Placebo
Participants will receive a single dose of either ABBV-722 Dose TBD or placebo.
Drug: ABBV-722 · Drug: Placebo
Participants will receive a single dose of either ABBV-722 Dose TBD or placebo.
Drug: ABBV-722 · Drug: Placebo
Participants who are Han Chinese will receive a single dose of ABBV-722 Dose D.
Drug: ABBV-722
Participants who are Japanese will receive a single dose of ABBV-722 Dose D.
Drug: ABBV-722
Participants will receive either ABBV-722 Dose E or placebo for 14 days.
Drug: ABBV-722 · Drug: Placebo
Participants will receive either ABBV-722 Dose F or placebo for 14 days.
Drug: ABBV-722 · Drug: Placebo
Participants will receive either ABBV-722 Dose A or placebo for 14 days.
Drug: ABBV-722 · Drug: Placebo
Participants will receive either ABBV-722 Dose G or placebo for 14 days.
Drug: ABBV-722 · Drug: Placebo
Participants will receive either ABBV-722 Dose TBD or placebo for 14 days.
Drug: ABBV-722 · Drug: Placebo
Oral Capsule
Oral Capsule
Number of Participants with Adverse Events Reported During Safety Evaluations
Safety evaluations will include AE monitoring, vital sign measurements (including orthostatic blood pressure and pulse rate), ECG variables, and clinical laboratory testing (hematology, chemistry, and urinalysis) as a measure of safety and tolerability for the entire study duration. Clinically significant abnormal changes in physical examination findings will be reported as AEs.
Time frame: Up to Day 44
Maximum Plasma Concentration (Cmax) of ABBV-722
Cmax of ABBV-722.
Time frame: Up to Day 21
Time to Cmax (Tmax) of ABBV-722
Tmax of ABBV-722.
Time frame: Up to Day 21
For Parts 1 and 2: Area Under the Concentration-Time Curve (AUC) from Time 0 to Time t (AUCt) of ABBV-722
AUCt of ABBV-722.
Time frame: Up to Day 8
For Parts 1 and 2: Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf) of ABBV-722
AUCinf of ABBV-722
Time frame: Up to Day 8
For Part 3: Observed Plasma Concentration at the End of the Dosing Interval (Ctrough) of ABBV-722
Ctrough of ABBV-722.
Time frame: Up to Day 21
For Part 3: AUC from Time 0 to the End of Dosing Interval (AUCtau) Following the First and Last Doses of ABBV-722
AUC from AUCtau following the first and last doses of ABBV-722.
Time frame: Up to Day 21
Terminal Phase Elimination Rate Constant (Beta) of ABBV-722
Beta of ABBV-722.
Time frame: Up to Day 21
Terminal Phase Elimination Half-Life (t1/2) of ABBV-722
t1/2 of ABBV-722.
Time frame: Up to Day 21
Dose Normalized Cmax
Dose normalized Cmax.
Time frame: Up to Day 21
Dose Normalized AUCs
Dose normalized AUCs.
Time frame: Up to Day 21
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2024 to primary completion in Jun 2026, 19 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABBV-722